430 EAST 29TH STREET 14TH FLOOR NEW YORK, NY 10016 Get Directions
430 EAST 29TH STREET 14TH FLOOR NEW YORK, NY 10016 Get Directions
CytoDel® Inc. was founded in 2012 to commercialize technology developed by its founders in the labs of Dr. Konstantin Ichtchenko at New York University School of Medicine (NYU). The Company’s patentedand proprietary technology enables recombinant derivatives of botulinum neurotoxin (BoNT) to be engineered to create highvalue products with customized properties, and to deliver active agents to therapeutic targets inside neurons. BoNT is bestknown as the active ingredient in pharmaceutical products such as Botox® (Allergan).
The ongoing development of each program is synergistic and a regulatory pathway via the Animal Rule for Biodefense can lead to an approval and potential revenue as early as 2021. This is a non-traditional routethrough a special group at the FDA. CytoDel's technology allows for the manipulation of BoNT at the molecular level, tocreate engineered “Botox-like” products with tailored pharmaceutical properties such as larger therapeutic window andlonger duration of action. The engineered BoNT can be used as a “Trojan horse” to deliver therapeutic antibodies insideof neurons with the lead program utilizing this technology in the development of antidotes for Botulism intoxication.
© Dun & Bradstreet, Inc. 2025. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.